GERMLINE AND SOMATIC BIOMARKER TESTING (INCLUDING LIQUID BIOPSY) FOR TARGETED TREATMENT IN PROSTATE CANCER (BRCA1/2, HOMOLOGOUS RECOMBINATION REPAIR GENE ALTERATIONS) - MEDICARE ADVANTAGE

Blue Cross Blue Shield of Michigan and Blue Care Network · PayerPolicy · BCBSM-2197830

Status: Active
Last checked by Backwork: September 30, 2026

Summary of the payer’s published policy. Not a coverage determination — confirm with Blue Cross Blue Shield of Michigan and Blue Care Network before submitting.

Get free alerts when Blue Cross Blue Shield of Michigan and Blue Care Network changes this policy

Free account. Policy pages stay open to everyone.

Codes in this policy

Each code’s status is what the policy records for it. This page does not show the policy’s criteria. Read them in the payer’s source.

Backwork has no codes on record for this policy. Check the source.